Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-230X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study ; volume:21 ; number:1 ; day:22 ; month:1 ; year:2021 ; pages:1-10 ; date:12.2021
BMC gastroenterology ; 21, Heft 1 (22.1.2021), 1-10, 12.2021
- Creator
-
Mühl, Laura
Becker, Emily
Müller, Tanja M.
Atreya, Raja
Atreya, Imke
Neurath, Markus F.
Zundler, Sebastian
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12876-021-01604-z
- URN
-
urn:nbn:de:101:1-2021031418154216976080
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mühl, Laura
- Becker, Emily
- Müller, Tanja M.
- Atreya, Raja
- Atreya, Imke
- Neurath, Markus F.
- Zundler, Sebastian
- SpringerLink (Online service)
Other Objects (12)
Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?
Predicting Therapeutic Response by in vivo Molecular Imaging in Inflammatory Bowel Diseases
Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study
Endoscopy as a Diagnostic Tool for Personalized Therapy in IBD: Prediction of Response to Biological Therapy
Oligonucleotides—A Novel Promising Therapeutic Option for IBD
Role of the IL23/IL17 Pathway in Crohn’s Disease
Endoscopic Therapy in Inflammatory Bowel Diseases
Quantitative contrast-enhanced ultrasound for monitoring vedolizumab therapy in inflammatory bowel disease patients: a pilot study
Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets
Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?
Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?
Predicting Therapeutic Response by in vivo Molecular Imaging in Inflammatory Bowel Diseases
Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study
Endoscopy as a Diagnostic Tool for Personalized Therapy in IBD: Prediction of Response to Biological Therapy
Oligonucleotides—A Novel Promising Therapeutic Option for IBD
Role of the IL23/IL17 Pathway in Crohn’s Disease
Endoscopic Therapy in Inflammatory Bowel Diseases
Quantitative contrast-enhanced ultrasound for monitoring vedolizumab therapy in inflammatory bowel disease patients: a pilot study
Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets
Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?
Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?
Predicting Therapeutic Response by in vivo Molecular Imaging in Inflammatory Bowel Diseases
Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study
Endoscopy as a Diagnostic Tool for Personalized Therapy in IBD: Prediction of Response to Biological Therapy
Oligonucleotides—A Novel Promising Therapeutic Option for IBD
Role of the IL23/IL17 Pathway in Crohn’s Disease
Endoscopic Therapy in Inflammatory Bowel Diseases
Quantitative contrast-enhanced ultrasound for monitoring vedolizumab therapy in inflammatory bowel disease patients: a pilot study
Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets
Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?